
Abeona Therapeutics (ABEO) Stock Forecast & Price Target
Abeona Therapeutics (ABEO) Analyst Ratings
Bulls say
Abeona Therapeutics Inc. is projecting substantial revenue growth, expecting approximately $32 million in top-line revenue for 2025 and $130.4 million in 2026. The current favorable market access situation indicates that coverage is likely to improve in the upcoming months, potentially enhancing revenue prospects. Additionally, the company's promising pipeline assets in gene therapies and plasma-based products could provide further incremental upside to the revenue forecasts, supporting a positive outlook on its financial performance.
Bears say
Abeona Therapeutics Inc faces several significant risks that contribute to a negative outlook on its stock. Key concerns include slower than anticipated market uptake for its lead product, pz-cel, in the United States, along with challenges in realizing its full value in international markets. Additionally, setbacks in the company’s earlier-stage pipeline programs and potential long-term dilution risk further complicate its financial stability and future growth prospects.
This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Abeona Therapeutics (ABEO) Analyst Forecast & Price Prediction
Start investing in Abeona Therapeutics (ABEO)
Order type
Buy in
Order amount
Est. shares
0 shares